Compare Stocks: CNTX, HUMA, RANI, and IMDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.24 -5.9%	$0.38	$0.24 ▼ $3.62	$23.48M	1.71	950,148 shs	1.34 million shs
HUMA Humacyte	$0.44 +24.1%	$0.57	$0.34 ▼ $1.90	$98.37M	2.44	5.56 million shs	20.74 million shs
IMDX Oncocyte	$3.06 +9.7%	$3.92	$2.42 ▼ $8.51	$91.30M	1.8	329,853 shs	177,680 shs
RANI Rani Therapeutics	$0.68 +1.5%	$0.81	$0.46 ▼ $3.87	$93.42M	0.69	572,240 shs	450,210 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-7.05%	-18.23%	-27.18%	-58.41%	-81.48%
HUMA Humacyte	-1.34%	-25.03%	-36.88%	-46.32%	-80.22%
IMDX Oncocyte	-6.69%	-19.36%	-30.60%	-40.76%	+278,999,900.00%
RANI Rani Therapeutics	-8.59%	-17.47%	-19.81%	+0.04%	+38.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.24 -5.9%	$0.38	$0.24 ▼ $3.62	$23.48M	1.71	950,148 shs	1.34 million shs
HUMA Humacyte	$0.44 +24.1%	$0.57	$0.34 ▼ $1.90	$98.37M	2.44	5.56 million shs	20.74 million shs
IMDX Oncocyte	$3.06 +9.7%	$3.92	$2.42 ▼ $8.51	$91.30M	1.8	329,853 shs	177,680 shs
RANI Rani Therapeutics	$0.68 +1.5%	$0.81	$0.46 ▼ $3.87	$93.42M	0.69	572,240 shs	450,210 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-7.05%	-18.23%	-27.18%	-58.41%	-81.48%
HUMA Humacyte	-1.34%	-25.03%	-36.88%	-46.32%	-80.22%
IMDX Oncocyte	-6.69%	-19.36%	-30.60%	-40.76%	+278,999,900.00%
RANI Rani Therapeutics	-8.59%	-17.47%	-19.81%	+0.04%	+38.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	2.50	Moderate Buy	$6.17	2,464.10% Upside
HUMA Humacyte	2.63	Moderate Buy	$5.63	1,179.86% Upside
IMDX Oncocyte	2.33	Hold	$10.50	243.14% Upside
RANI Rani Therapeutics	2.83	Moderate Buy	$8.75	1,186.76% Upside

Current Analyst Ratings Breakdown

Latest CNTX, HUMA, RANI, and IMDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	CNTX Context Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/7/2026	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/6/2026	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Equal Weight	$0.50
10/6/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/21/2026	IMDX Oncocyte	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/21/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	IMDX Oncocyte	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$9.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
HUMA Humacyte	$2.12M	57.56	N/A	N/A	$0.02 per share	21.98
IMDX Oncocyte	$4.05M	24.72	N/A	N/A	($1.10) per share	-2.78
RANI Rani Therapeutics	$1.63M	58.15	N/A	N/A	$0.34 per share	2.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
IMDX Oncocyte	-$50.22M	-$1.49	N/A	N/A	N/A	-2,955.63%	N/A	-107.52%	N/A
RANI Rani Therapeutics	-$29.67M	-$0.27	N/A	N/A	N/A	N/A	-104.60%	-65.17%	11/5/2026 (Estimated)

Latest CNTX, HUMA, RANI, and IMDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	HUMA Humacyte	-$0.09	N/A	N/A	N/A	$0.77 million	N/A
11/5/2026	Q3 2026	RANI Rani Therapeutics	-$0.05	N/A	N/A	N/A	$1.28 million	N/A
11/4/2026	Q3 2026	CNTX Context Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	-$0.04	+$0.01	-$0.04	$0.93 million	$1.71 million
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/10/2026	Q2 2026	IMDX Oncocyte	N/A	-$0.23	N/A	-$0.31	N/A	$0.24 million
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
IMDX Oncocyte	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	5.81	5.81
HUMA Humacyte	2.07	6.21	5.74
IMDX Oncocyte	N/A	2.00	1.98
RANI Rani Therapeutics	N/A	5.31	5.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
HUMA Humacyte	44.71%
IMDX Oncocyte	55.35%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	4.80%
HUMA Humacyte	3.10%
IMDX Oncocyte	2.21%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
HUMA Humacyte	184	277.80 million	269.19 million	Optionable
IMDX Oncocyte	58	32.72 million	32.00 million	N/A
RANI Rani Therapeutics	69	139.40 million	102.14 million	Optionable

CNTX, HUMA, RANI, and IMDX Headlines

Recent News About These Companies

Rani Therapeutics to Participate in the Chardan Healthcare Conference

October 13 at 4:05 PM | globenewswire.com

Rani Therapeutics Holdings, Inc. Announces Acceptance Of RaniPill Capsule Platform Technology Into U.S. Food And Drug Administration Emerging Technology Program

October 6, 2026 | marketscreener.comM

Rani Therapeutics' RaniPill Accepted Into FDA Emerging Technology Program

October 5, 2026 | rttnews.com

FDA accepts Rani Therapeutics' RaniPill platform into emerging tech program

October 5, 2026 | streetinsider.com

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

October 5, 2026 | globenewswire.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 23, 2026 | marketbeat.com

Rani Therapeutics to Participate in Upcoming September Conferences

September 8, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)

August 25, 2026 | theglobeandmail.com

Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

August 20, 2026 | theglobeandmail.com

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

August 13, 2026 | globenewswire.com

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 10, 2026 | markets.businessinsider.com

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4, 2026 | quiverquant.comQ

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

July 15, 2026 | globenewswire.com

Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup

July 14, 2026 | donanimhaber.comD

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

July 13, 2026 | money.usnews.com

Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates

July 13, 2026 | pharmabiz.comP

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?

July 10, 2026 | kalkinemedia.comK

China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics

July 10, 2026 | yicaiglobal.comY

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

July 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CNTX, HUMA, RANI, and IMDX Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.24 -0.02 (-5.91%)

Closing price 04:00 PM Eastern

Extended Trading

$0.26 +0.02 (+7.69%)

As of 07:54 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Humacyte NASDAQ:HUMA

$0.44 +0.09 (+24.12%)

Closing price 04:00 PM Eastern

Extended Trading

$0.43 -0.01 (-1.25%)

As of 07:54 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Oncocyte NASDAQ:IMDX

$3.06 +0.27 (+9.68%)

Closing price 04:00 PM Eastern

Extended Trading

$3.06 +0.00 (+0.16%)

As of 07:30 PM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Rani Therapeutics NASDAQ:RANI

$0.68 +0.01 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 +0.02 (+2.50%)

As of 07:30 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTX, HUMA, RANI, and IMDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTX, HUMA, RANI, and IMDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTX, HUMA, RANI, and IMDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNTX, HUMA, RANI, and IMDX Company Descriptions

Context Therapeutics NASDAQ:CNTX

Humacyte NASDAQ:HUMA

Oncocyte NASDAQ:IMDX

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTX, HUMA, RANI, and IMDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTX, HUMA, RANI, and IMDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTX, HUMA, RANI, and IMDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNTX, HUMA, RANI, and IMDX Company Descriptions

Context Therapeutics NASDAQ:CNTX

Humacyte NASDAQ:HUMA

Oncocyte NASDAQ:IMDX

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools